<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>RECTIV- nitroglycerin ointment </strong><br>Aptalis Pharma US, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<span class="Bold">These highlights do not include all the information needed to use RECTIV<span class="Sup">®</span> (nitroglycerin) Ointment 0.4% safely and effectively. See full prescribing information for RECTIV.</span><br><br><span class="Bold">RECTIV (nitroglycerin) Ointment 0.4%, for intra-anal use</span><br><span class="Bold">Initial U.S. Approval: 1955</span>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">RECTIV is a nitrate vasodilator indicated for the treatment of moderate to severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> associated with chronic <span class="product-label-link" type="condition" conceptid="76725" conceptname="Anal fissure">anal fissure</span> (<a href="#splSectionPLRIndicationsUsage">1</a>).
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">Apply 1 inch of ointment (375 mg of ointment equivalent to 1.5 mg of nitroglycerin) intra-anally every 12 hours for up to 3 weeks (<a href="#splSectionPLRDosageAdministration">2</a>). </p>
<p class="Highlighta"><br>RECTIV ointment is not for oral, ophthalmic, or intravaginal use (<a href="#splSectionPLRDosageAdministration">2</a>)
 </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Ointment 0.4% w/w (4 mg nitroglycerin/1 g ointment) (<a href="#splSectionPLRDosageFormsStrength">3</a>)
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li>Use of PDE5 inhibitors (e.g. sildenafil, vardenafil and tadalafil) as these are shown to potentiate the hypotensive effects of organic nitrates. (<a href="#splSection1">4.1</a>).</li>
<li>Severe <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (<a href="#splSection2">4.2</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased intracranial pressure</span> (<a href="#splSection3">4.3</a>)</li>
<li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to nitroglycerin, other nitrates and nitrites, or any components of the ointment. (<a href="#splSection4">4.4</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span>: Venous and arterial dilatation as a consequence of nitroglycerin treatment can result in <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. Exercise caution when treating patients with any of the following conditions: blood <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span>, existing <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, cardiomyopathies, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span>, or poor cardiac function for other reasons (<a href="#splSection5">5.1</a>).</li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>: Nitroglycerin produces dose-related <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> which may be severe (<a href="#splSection6">5.2</a>)</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions are <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>. (<a href="#splSectionPLRAdverseReactions">6</a>) </p>
<p class="Highlighta"><br><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Aptalis Pharma US, Inc. at 1-800-472-2634, or FDA at 1-800-FDA-1088 or </span><span class="Bold Italics">www.fda.gov/medwatch</span>.
 </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>PDE5 inhibitors: potentiation of hypotensive effects of organic nitrates; concomitant use is contraindicated. (<a href="#splSection1">4.1</a>, <a href="#splSection7">7.1</a>)</li>
<li>Antihypertensives: possible additive hypotensive effects. (<a href="#splSection8">7.2</a>)</li>
<li>Aspirin: increased nitroglycerin levels. (<a href="#splSection9">7.3</a>)</li>
<li>Tissue-type <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">Plasminogen</span> Activator (t-PA): decreased thrombolytic effect. (<a href="#splSection10">7.4</a>)</li>
<li>Heparin: anticoagulant effect of heparin may be reduced. Monitor APTT. (<a href="#splSection11">7.5</a>)</li>
<li>Ergotamine: increased bioavailability of ergotamine. (<a href="#splSection12">7.6</a>)</li>
<li>Alcohol: Additive vasodilatory effects to nitroglycerin. Consumption of alcohol should be avoided. (<a href="#splSection13">7.7</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 7/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">
1 INDICATIONS AND USAGE
</a></h1>
<h1><a href="#section-2" class="toc">
2 DOSAGE AND ADMINISTRATION
</a></h1>
<h1><a href="#section-3" class="toc">
3 DOSAGE FORMS AND STRENGTHS
</a></h1>
<h1><a href="#section-4" class="toc">
4 CONTRAINDICATIONS
</a></h1>
<h2><a href="#section-4.1" class="toc">
4.1 PDE5 inhibitor use
</a></h2>
<h2><a href="#section-4.2" class="toc">
4.2 Severe <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>
</a></h2>
<h2><a href="#section-4.3" class="toc">
4.3 <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased intracranial pressure</span>
</a></h2>
<h2><a href="#section-4.4" class="toc">
4.4 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>
</a></h2>
<h1><a href="#section-5" class="toc">
5 WARNINGS AND PRECAUTIONS
</a></h1>
<h2><a href="#section-5.1" class="toc">
5.1 <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular disorders</span>
</a></h2>
<h2><a href="#section-5.2" class="toc">
5.2 <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>
</a></h2>
<h1><a href="#section-6" class="toc">
6 ADVERSE REACTIONS
</a></h1>
<h1><a href="#section-7" class="toc">
7 DRUG INTERACTIONS
</a></h1>
<h2><a href="#section-7.1" class="toc">
7.1 PDE5 inhibitors
</a></h2>
<h2><a href="#section-7.2" class="toc">
7.2 Antihypertensives
</a></h2>
<h2><a href="#section-7.3" class="toc">
7.3 Aspirin
</a></h2>
<h2><a href="#section-7.4" class="toc">
7.4 Tissue-type <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">Plasminogen</span> Activator (t-PA)
</a></h2>
<h2><a href="#section-7.5" class="toc">
7.5 Heparin
</a></h2>
<h2><a href="#section-7.6" class="toc">
7.6 Ergotamine
</a></h2>
<h2><a href="#section-7.7" class="toc">
7.7 Alcohol
</a></h2>
<h1><a href="#section-8" class="toc">
8 USE IN SPECIFIC POPULATIONS
</a></h1>
<h2><a href="#section-8.1" class="toc">
8.1 Pregnancy
</a></h2>
<h2><a href="#section-8.2" class="toc">
8.3 Nursing Mothers
</a></h2>
<h2><a href="#section-8.3" class="toc">
8.4 Pediatric Use
</a></h2>
<h2><a href="#section-8.4" class="toc">
8.5 Geriatric Use
</a></h2>
<h1><a href="#section-9" class="toc">
10 OVERDOSAGE
</a></h1>
<h1><a href="#section-10" class="toc">
11 DESCRIPTION
</a></h1>
<h1><a href="#section-11" class="toc">
12 CLINICAL PHARMACOLOGY
</a></h1>
<h2><a href="#section-11.1" class="toc">
12.1 Mechanism of Action
</a></h2>
<h2><a href="#section-11.2" class="toc">
12.2 Pharmacodynamics
</a></h2>
<h2><a href="#section-11.3" class="toc">
12.3 Pharmacokinetics
</a></h2>
<h1><a href="#section-12" class="toc">
13 NONCLINICAL TOXICOLOGY
</a></h1>
<h2><a href="#section-12.1" class="toc">
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</a></h2>
<h1><a href="#section-13" class="toc">
14 CLINICAL STUDIES
</a></h1>
<h1><a href="#section-14" class="toc">
16 HOW SUPPLIED/STORAGE AND HANDLING
</a></h1>
<h1><a href="#section-15" class="toc">
17 PATIENT COUNSELING INFORMATION
</a></h1>
<h2><a href="#section-15.1" class="toc">
17.1 Interaction with PDE5 inhibitors
</a></h2>
<h2><a href="#section-15.2" class="toc">
17.2 <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>
</a></h2>
<h2><a href="#section-15.3" class="toc">
17.3 <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headaches</span>
</a></h2>
<h2><a href="#section-15.4" class="toc">
17.4 <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>
</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="splSectionPLRIndicationsUsage"></a><a name="section-1"></a><p></p>
<h1>
1 INDICATIONS AND USAGE
</h1>
<p class="First">RECTIV<span class="Sup">®</span> (nitroglycerin) Ointment 0.4% is indicated for the treatment of moderate to severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> associated with chronic <span class="product-label-link" type="condition" conceptid="76725" conceptname="Anal fissure">anal fissure</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="splSectionPLRDosageAdministration"></a><a name="section-2"></a><p></p>
<h1>
2 DOSAGE AND ADMINISTRATION
</h1>
<p class="First">Apply 1 inch of ointment (375 mg of ointment equivalent to 1.5 mg of nitroglycerin) intra-anally every 12 hours for up to 3 weeks. A finger covering, such as plastic-wrap, disposable surgical glove or a finger cot, should be placed on the finger to apply the ointment. To obtain a 1.5 mg dose of nitroglycerin, the covered finger is laid alongside the 1 inch dosing line on the carton.</p>
<div class="Figure"><img alt="
rectiv-01
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=603aa9ed-54c4-4a35-ade4-690fa44850e4&amp;name=rectiv-01.jpg"></div>
<p>Refer to carton for accurate dosage guide.</p>
<p>The tube is gently squeezed until a line of ointment the length of the measuring line is expressed onto the covered finger. The ointment is gently inserted into the anal canal using the covered finger no further than to the first finger joint and the ointment is applied around the side of the anal canal. If this cannot be achieved due to <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, application of the ointment should be made directly to the outside of the anus. Treatment may be continued for up to three weeks.</p>
<p>RECTIV ointment is not for oral, ophthalmic, or intravaginal use. Hands should be washed after application of the ointment.</p>
<p>See <a href="#splSectionPPI">Patients Instruction for Use</a>.
</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="splSectionPLRDosageFormsStrength"></a><a name="section-3"></a><p></p>
<h1>
3 DOSAGE FORMS AND STRENGTHS
</h1>
<p class="First">Ointment, 0.4% w/w (4 mg/1 g) in 30 g tubes. </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="splSectionPLRContraindications"></a><a name="section-4"></a><p></p>
<h1>
4 CONTRAINDICATIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection1"></a><a name="section-4.1"></a><p></p>
<h2>
4.1 PDE5 inhibitor use
</h2>
<p class="First">Administration of RECTIV is contraindicated in patients who are using a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5), such as sildenafil, vardenafil, and tadalafil, as these are shown to potentiate the hypotensive effects of organic nitrates [see <a href="#splSection7">7.1 DRUG INTERACTIONS</a>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection2"></a><a name="section-4.2"></a><p></p>
<h2>
4.2 Severe <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>
</h2>
<p class="First">RECTIV is contraindicated in patients with severe <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection3"></a><a name="section-4.3"></a><p></p>
<h2>
4.3 <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased intracranial pressure</span>
</h2>
<p class="First">RECTIV is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection4"></a><a name="section-4.4"></a><p></p>
<h2>
4.4 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>
</h2>
<p class="First">RECTIV is contraindicated in patients who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to it or to other nitrates or nitrites. <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin reactions</span> consistent with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> have been observed with organic nitrates.</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="splSectionPLRWarnings"></a><a name="section-5"></a><p></p>
<h1>
5 WARNINGS AND PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection5"></a><a name="section-5.1"></a><p></p>
<h2>
5.1 <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular disorders</span>
</h2>
<p class="First">Venous and arterial dilatation as a consequence of nitroglycerin treatment including RECTIV, can decrease venous blood returning to the heart and reduce arterial <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> and systolic pressure. Exercise caution when treating patients with any of the following conditions: blood <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span>, existing <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, cardiomyopathies, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span>, or poor cardiac function for other reasons. If patients with any of these conditions are treated with RECTIV, monitor cardiovascular status and clinical condition. The adverse reactions of RECTIV are likely to be more pronounced in the elderly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection6"></a><a name="section-5.2"></a><p></p>
<h2>
5.2 <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>
</h2>
<p class="First">RECTIV produces dose-related <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, which may be severe. Tolerance to <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> occurs.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="splSectionPLRAdverseReactions"></a><a name="section-6"></a><p></p>
<h1>
6 ADVERSE REACTIONS
</h1>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>The most common adverse reaction of RECTIV (nitroglycerin) Ointment 0.4% applied to the anal canal is <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> may be recurrent following each dose. <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headaches</span> are typically of short duration and can be treated with an analgesic, e.g. acetaminophen, and are reversible upon discontinuation of treatment.</p>
<p>In Study REC-C-001, a double-blind, placebo-controlled trial in patients with a painful chronic <span class="product-label-link" type="condition" conceptid="76725" conceptname="Anal fissure">anal fissure</span>, the most frequent (≥ 2%) adverse reactions reported were as follows (Table 1):</p>
<table width="80%">
<caption><span>
Table 1: Incidence of Adverse Reactions (≥ 2%) in Study REC-C-001
</span></caption>
<col align="left" width="40%">
<col align="center" width="15%">
<col align="center" width="15%">
<col align="center" width="15%">
<col align="center" width="15%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule" align="left"></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2">
<span class="Bold">RECTIV</span><br><span class="Bold">N = 123</span>
</td>
<td class="Botrule Lrule Rrule" align="center" colspan="2">
<span class="Bold">Placebo</span><br><span class="Bold">N = 124</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
<span class="Bold">System Organ Class</span><br>   Preferred term
</td>
<td class="Botrule Lrule Rrule" align="center">
<span class="Bold">Patients</span><br><span class="Bold">n (%)</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
<span class="Bold">Events</span><br><span class="Bold">n</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
<span class="Bold">Patients</span><br><span class="Bold">n (%)</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
<span class="Bold">Events</span><br><span class="Bold">n</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span></td>
<td class="Botrule Lrule Rrule" align="center" colspan="4"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
79 (64)
</td>
<td class="Botrule Lrule Rrule" align="center">
938
</td>
<td class="Botrule Lrule Rrule" align="center">
51 (41)
</td>
<td class="Botrule Lrule Rrule" align="center">
225
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left">
   <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>
</td>
<td class="Botrule Lrule Rrule" align="center">
6 (5)
</td>
<td class="Botrule Lrule Rrule" align="center">
26
</td>
<td class="Botrule Lrule Rrule" align="center">
0
</td>
<td class="Botrule Lrule Rrule" align="center">
0
</td>
</tr>
</tbody>
</table>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></span></p>
<p>Transient episodes of light-headedness, occasionally related to blood pressure changes, also may occur. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> (including <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>) occurs infrequently, but in some patients may be severe enough to warrant discontinuation of therapy.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> and <span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">application site reactions</span> (including <span class="product-label-link" type="condition" conceptid="4080559" conceptname="Baboon syndrome">drug rash</span> and <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>) have been reported rarely.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">Methemoglobinemia</span></span></p>
<p>In rare cases, therapeutic doses of organic nitrates have caused <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> (see <a href="#splSectionPLROverdose">10 OVERDOSAGE</a>).
</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="splSectionPLRDrugInteract"></a><a name="section-7"></a><p></p>
<h1>
7 DRUG INTERACTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection7"></a><a name="section-7.1"></a><p></p>
<h2>
7.1 PDE5 inhibitors
</h2>
<p class="First">Phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil, vardenafil, and tadalafil have been shown to potentiate the hypotensive effects of organic nitrates.</p>
<p>The time course of the interaction appears to be related to the half-life of the PDE5 inhibitor, however, the dose <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> of this interaction has not been studied. Use of RECTIV within a few days of PDE5 inhibitors is contraindicated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection8"></a><a name="section-7.2"></a><p></p>
<h2>
7.2 Antihypertensives
</h2>
<p class="First">Patients receiving antihypertensive drugs, beta-adrenergic blockers, and other nitrates should be observed for possible additive hypotensive effects when using RECTIV. Marked <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> has been reported when calcium channel blockers and organic nitrates were used concomitantly.</p>
<p>Beta-blockers blunt the <span class="product-label-link" type="condition" conceptid="444070" conceptname="Tachycardia">reflex tachycardia</span> produced by nitroglycerin without preventing its hypotensive effects. If beta-blockers are used with RECTIV in patients with <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, additional hypotensive effects may occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection9"></a><a name="section-7.3"></a><p></p>
<h2>
7.3 Aspirin
</h2>
<p class="First">Coadministration of aspirin (at doses between 500 mg and 1000 mg) and nitroglycerin has been reported to result in increased nitroglycerin maximum concentrations by as much as 67% and AUC by 73% when administered as a single dose. The pharmacological effects of RECTIV may be enhanced by concomitant administration of aspirin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection10"></a><a name="section-7.4"></a><p></p>
<h2>
7.4 Tissue-type <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">Plasminogen</span> Activator (t-PA)
</h2>
<p class="First">Intravenous administration of nitroglycerin decreases the thrombolytic effect of tissue-type <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">plasminogen</span> activator (t-PA). Plasma levels of t-PA are reduced when coadministered with nitroglycerin. Therefore, caution should be observed in patients receiving RECTIV during t-PA therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection11"></a><a name="section-7.5"></a><p></p>
<h2>
7.5 Heparin
</h2>
<p class="First">Although an interaction has been reported between intravenous heparin and intravenous nitroglycerin (resulting in a decrease in the anticoagulant effect of heparin), the data are not consistent. If patients are to receive intravenous heparin and RECTIV concurrently, the anticoagulation status of the patient must be checked.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection12"></a><a name="section-7.6"></a><p></p>
<h2>
7.6 Ergotamine
</h2>
<p class="First">Oral administration of nitroglycerin markedly decreases the first-pass metabolism of dihydroergotamine and consequently increases its oral bioavailability. Ergotamine is known to precipitate <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>. Therefore the possibility of <span class="product-label-link" type="condition" conceptid="4201303" conceptname="Ergotism">ergotism</span> in patients receiving RECTIV should be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection13"></a><a name="section-7.7"></a><p></p>
<h2>
7.7 Alcohol
</h2>
<p class="First">The vasodilating effects of nitroglycerin have been shown to be additive to the effects observed with alcohol.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="splSectionPLRPopulations"></a><a name="section-8"></a><p></p>
<h1>
8 USE IN SPECIFIC POPULATIONS
</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="splSectionPLRPregnancy"></a><a name="section-8.1"></a><p></p>
<h2>
8.1 Pregnancy
</h2>
<p class="First"><span class="Italics">Pregnancy Category C</span></p>
<p>Animal reproduction and <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> studies have not been conducted with RECTIV. Nitroglycerin was not teratogenic when administered by topical or dietary route. There are no adequate and well-controlled studies in pregnant women. RECTIV should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p>Teratology studies in rats and rabbits were conducted with topically applied nitroglycerin ointment at doses up to 80 mg/kg/day and 240 mg/kg/day, respectively. No toxic effects on dams or fetuses were seen at any dose tested.</p>
<p>A <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> study was conducted in rats with nitroglycerin administered in the diet at levels up to 1% content (approximately 430 mg/kg/day) on days 6 to 15 of gestation. In offspring of the high-dose group, an increased but not statistically significant incidence of <span class="product-label-link" type="condition" conceptid="201061" conceptname="Diaphragmatic hernia">diaphragmatic hernias</span> was noted together with decreased hyoid bone ossification. The latter finding probably reflects delayed development, thus indicating no clear evidence of a potential teratogenic effect of nitroglycerin.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="splSectionPLRNursing"></a><a name="section-8.2"></a><p></p>
<h2>
8.3 Nursing Mothers
</h2>
<p class="First">It is not known whether nitroglycerin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when RECTIV is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="splSectionPLRPediatric"></a><a name="section-8.3"></a><p></p>
<h2>
8.4 Pediatric Use
</h2>
<p class="First">The safety and effectiveness of RECTIV in pediatric patients under 18 years of age have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="splSectionPLRGeriatric"></a><a name="section-8.4"></a><p></p>
<h2>
8.5 Geriatric Use
</h2>
<p class="First">Clinical studies of RECTIV did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Clinical data from the published literature indicate that the elderly demonstrate increased sensitivity to nitrates, which may be therapeutic but also manifest by more frequent or severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and related <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span>. Increased sensitivity may reflect the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="splSectionPLROverdose"></a><a name="section-9"></a><p></p>
<h1>
10 OVERDOSAGE
</h1>
<p class="First">Nitroglycerin toxicity is generally mild. The estimated adult oral lethal dose of nitroglycerin is 200 mg to 1,200 mg. Infants may be more susceptible to toxicity from nitroglycerin. Consultation with a poison center should be considered.</p>
<p>Laboratory determinations of serum levels of nitroglycerin and its metabolites are not widely available, and such determinations have, in any event, no established role in the management of nitroglycerin <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</p>
<p>No data are available to suggest physiological maneuvers (e.g., maneuvers to change the pH of the urine) that might accelerate elimination of nitroglycerin and its active metabolites. Similarly, it is not known which if any of these substances can usefully be removed from the body by hemodialysis.</p>
<p>No specific antagonist to the vasodilator effects of nitroglycerin is known, and no intervention has been subject to controlled study as a therapy of nitroglycerin <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Because the <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> associated with nitroglycerin <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> is the result of venodilatation and arterial <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span>, prudent therapy in this situation should be directed toward increase in central fluid volume. Passive elevation of the patient's legs may be sufficient, but intravenous infusion of normal saline or similar fluid may also be necessary.</p>
<p>The use of epinephrine or other arterial vasoconstrictors in this setting is not recommended.</p>
<p>In patients with <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> or <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, therapy resulting in central volume expansion is not without hazard. Treatment of RECTIV <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> in these patients may be subtle and difficult, and invasive monitoring may be required.</p>
<br><p><span class="Italics"><span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">Methemoglobinemia</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">Methemoglobinemia</span> has been rarely reported with organic nitrates. The diagnosis should be suspected in patients who exhibit signs of impaired oxygen delivery despite adequate arterial PO<span class="Sub">2</span>. Classically, methemoglobinemic blood is described as chocolate brown, without color change on exposure to air.</p>
<p>If <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> is present, intravenous administration of methylene blue, 1 to 2 mg/kg of body weight, may be required.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="splSectionPLRDescription"></a><a name="section-10"></a><p></p>
<h1>
11 DESCRIPTION
</h1>
<p class="First">Nitroglycerin is 1,2,3,-propanetriol trinitrate, an organic nitrate whose structural formula is as follows:</p>
<p>CH<span class="Sub">2</span>-ONO<span class="Sub">2</span><br> |<br>CH-ONO<span class="Sub">2</span><br> |<br>CH<span class="Sub">2</span>-ONO<span class="Sub">2</span></p>
<p>and whose molecular weight is 227.09. RECTIV (nitroglycerin) Ointment 0.4% contains 0.4% nitroglycerin w/w (4 mg nitroglycerin/1 g ointment), propylene glycol, lanolin, sorbitan sesquioleate, paraffin wax, and white petrolatum. RECTIV (nitroglycerin) Ointment 0.4% is available in tubes with a one-inch dosing line on the carton allowing the measurement of approximately 375 mg of nitroglycerin ointment 0.4% (1.5 mg nitroglycerin) for application.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="splSectionPLRClinicalPharm"></a><a name="section-11"></a><p></p>
<h1>
12 CLINICAL PHARMACOLOGY
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="splSectionPLRMechAction"></a><a name="section-11.1"></a><p></p>
<h2>
12.1 Mechanism of Action
</h2>
<p class="First">Nitroglycerin forms free radical nitric oxide (NO), which activates guanylate cyclase, resulting in an increase of guanosine 3',5'-monophosphate (cyclic GMP) in smooth muscle and other tissues. This leads to dephosphorylation of myosin light chains, which regulates the contractile state in smooth muscle and results in <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span>.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="splSectionPLRPharmacodynamics"></a><a name="section-11.2"></a><p></p>
<h2>
12.2 Pharmacodynamics
</h2>
<p class="First">The principal pharmacological action of nitroglycerin is relaxation of vascular smooth muscle. Intra-anal application of nitroglycerin reduces sphincter tone and resting intra-anal pressure.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="splSectionPLRPharmacokinetics"></a><a name="section-11.3"></a><p></p>
<h2>
12.3 Pharmacokinetics
</h2>
<p class="First"><span class="Bold">Absorption:</span> In six healthy subjects, the average absolute bioavailability of nitroglycerin applied to the anal canal as a 0.2% w/w ointment was approximately 50% of the 0.75 mg nitroglycerin dose.</p>
<p><span class="Bold">Distribution:</span> The volume of distribution of nitroglycerin following intravenous administration is about 3 L/kg. At plasma concentrations between 50 and 500 ng/mL, the binding of nitroglycerin to plasma proteins is approximately 60%, while that of 1,2- and 1,3-dinitroglycerin is 60% and 30%, respectively.</p>
<p><span class="Bold">Metabolism:</span> Nitroglycerin is metabolized by a liver reductase enzyme to glycerol di- and mononitrate metabolites and ultimately to glycerol and organic nitrate. Known sites of extrahepatic metabolism include red blood cells and vascular walls. In addition to nitroglycerin, the two major metabolites, 1,2- and 1,3- dinitroglycerols are found in plasma. The contribution of metabolites to the relaxation of the internal anal sphincter is unknown. The dinitrates are further metabolized to nonvasoactive mononitrates and ultimately to glycerol and <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span>.</p>
<p><span class="Bold">Elimination:</span> Metabolism is the primary route of drug elimination. Nitroglycerin plasma concentrations decrease rapidly with a mean elimination half-life of two to three minutes. Half-life values range from 1.5 to 7.5 minutes. Clearance (13.6 L/min) greatly exceeds hepatic blood flow.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="splSectionPLRNonClinical"></a><a name="section-12"></a><p></p>
<h1>
13 NONCLINICAL TOXICOLOGY
</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="splSectionPLRPrecautionsCarcinogen"></a><a name="section-12.1"></a><p></p>
<h2>
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<p class="First">Animal carcinogenicity studies with topically applied nitroglycerin have not been performed.</p>
<p>Rats receiving up to 434 mg/kg/day of dietary nitroglycerin for 2 years developed dose-related fibrotic and neoplastic changes in liver, including carcinomas, and interstitial cell tumors in testes. At the highest dose, the incidence of hepatocellular carcinomas was 52% compared to 0% in untreated controls. Incidence of testicular tumors were 52% vs. 8% in controls. Lifetime dietary administration of up to 1058 mg/kg/day of nitroglycerin was not tumorigenic in mice.</p>
<p>Nitroglycerin was mutagenic in the <span class="Italics">in vitro</span> bacterial reverse mutation (Ames) assay with <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium</span>. A similar mutation in this <span class="Italics">S. typhimurium</span> was also reported with other NO donors. There was no evidence of clastogenic potential in multiple assays including a rodent dominant lethal assay, an <span class="Italics">in vitro</span> Chinese Hamster Ovary assay that was conducted in the absence of metabolic activation, and several <span class="Italics">in vivo</span> chromosomal aberration assays conducted in rats and dogs.</p>
<p>In a three-generation reproduction study, rats received dietary nitroglycerin at doses up to approximately 434 mg/kg/day for 6 months prior to mating of the F<span class="Sub">0</span> generation with treatment continuing through successive F<span class="Sub">1</span> and F<span class="Sub">2</span> generations. The high dose was associated with decreased feed intake and body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> in both sexes at all matings. No specific effect on the fertility of the F<span class="Sub">0</span> generation was seen. <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">Infertility</span> noted in subsequent generations, however, was attributed to increased interstitial cell tissue and aspermatogenesis in the high-dose males.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="splSectionPLRClinicalStudies"></a><a name="section-13"></a><p></p>
<h1>
14 CLINICAL STUDIES
</h1>
<p class="First">RECTIV ointment was evaluated in a 3-week double-blind, randomized, multi-center, placebo-controlled study. Patients with a painful chronic <span class="product-label-link" type="condition" conceptid="76725" conceptname="Anal fissure">anal fissure</span> for at least 6 weeks and moderate or severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> prior to treatment (≥ 50 mm on the 100 mm visual analog scale, VAS) were randomized to receive 0.4% (1.5 mg) nitroglycerin or placebo ointment applied to the anal canal every 12 hours. <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> as assessed by the change in VAS from baseline to Days 14-18 was lower in patients receiving 0.4% ointment compared to placebo. The mean change from baseline was 44 mm for RECTIV and 37 mm for placebo. The difference in the mean change in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> between RECTIV and placebo was -7.0 mm (95% Confidence Interval: -13.6 to -0.4 mm).</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="splSectionPLRHowSupplied"></a><a name="section-14"></a><p></p>
<h1>
16 HOW SUPPLIED/STORAGE AND HANDLING
</h1>
<p class="First"><span class="Bold">RECTIV (nitroglycerin) Ointment 0.4%</span> is available in 30 g (NDC 58914-301-80) aluminum tubes with polyethylene screw caps.</p>
<p>Store at 20°-25°C (68°-77°F); excursions permitted between 15°-30°C (59°-86°F). [See USP Controlled Room Temperature].</p>
<p>Keep the tube tightly closed. Use within 8 weeks of first opening.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="splSectionPLRPatientInfo"></a><a name="section-15"></a><p></p>
<h1>
17 PATIENT COUNSELING INFORMATION
</h1>
<p class="First">See FDA-approved patient labeling (<a href="#splSectionPPI">Patient Information and Instructions for Use</a>)</p>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection14"></a><a name="section-15.1"></a><p></p>
<h2>
17.1 Interaction with PDE5 inhibitors
</h2>
<p class="First">Advise patient not to use RECTIV with medications for <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span> such as Viagra (sildenafil), Levitra (vardenafil), and Cialis (tadalafil). These products have been shown to increase the hypotensive effects of RECTIV and other nitrate drugs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection15"></a><a name="section-15.2"></a><p></p>
<h2>
17.2 <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>
</h2>
<p class="First">Advise patients that treatment with RECTIV may be associated with light-headedness on standing, especially just after rising from a lying or seated position. The effect may be more frequent in patients who have also consumed alcohol, since alcohol use contributes to <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. Advise patients to stand up from the supine or sitting position slowly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection16"></a><a name="section-15.3"></a><p></p>
<h2>
17.3 <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headaches</span>
</h2>
<p class="First">Advise patients that <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> sometimes accompany treatment with RECTIV. For patients who get these <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, the <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> may indicate the activity of the drug. Tolerance to <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> develops. Advise patients that if they experience <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> they should not alter the schedule of their RECTIV treatment to avoid the occurrence of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. An analgesic, such as acetaminophen, may be used to prevent or relieve the <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection17"></a><a name="section-15.4"></a><p></p>
<h2>
17.4 <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>
</h2>
<p class="First">Advise patients that <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> has been reported as a side-effect of treatment with RECTIV.</p>
<p>Advise patients not to drive or operate machinery immediately after applying RECTIV.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection18"></a><a name="section-15.5"></a><p></p>
<h2>
17.5 FDA-Approved Patient Labeling
</h2>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="splSectionPPI"></a><a name="section-16"></a><p></p>
<h1>
Patient Information
</h1>
<p class="First"><span class="Bold">RECTIV<span class="Sup">®</span> [REC-tiv]</span><br>(Nitroglycerin) Ointment 0.4%</p>
<table width="100%">
<col align="center" width="100%">
<tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule" align="center"><span class="Bold">IMPORTANT: For intra-anal use only</span></td></tr></tbody>
</table>
<p>Read the Patient Information that comes with RECTIV before you start using the product and each time you get a refill because there may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment. If you have any questions about RECTIV, ask your healthcare provider.</p>
<p><br><span class="Bold">What is RECTIV?</span></p>
<p>RECTIV is a prescription medicine used to treat moderate to severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> caused by chronic <span class="product-label-link" type="condition" conceptid="76725" conceptname="Anal fissure">anal fissures</span>. An <span class="product-label-link" type="condition" conceptid="76725" conceptname="Anal fissure">anal fissure</span> is a tear in the skin lining the anal canal.</p>
<p>RECTIV is not suitable for children and adolescents under the age of 18 years because it has not been assessed in people in this age group.</p>
<p><br><span class="Bold">Who should not use RECTIV?</span></p>
<p><span class="Bold">Do not use RECTIV if you:</span></p>
<ul class="Disc">
<li>are taking a medicine for <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span> (male <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>), for example Viagra (sildenafil), Cialis (tadalafil) or Levitra (vardenafil).</li>
<li>have been told by your doctor that you have severe <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (low numbers of red blood cells in your blood)</li>
<li>have <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span> or high pressure within your skull e.g. following head <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in your brain</li>
<li>are allergic to any of the ingredients in RECTIV or if you have had <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to similar medicines in the past. See the end of this leaflet for a list of ingredients in RECTIV.</li>
</ul>
<p><br><span class="Bold">What should I tell my healthcare provider before using RECTIV?</span></p>
<p><span class="Bold">Tell your healthcare provider about all your medical conditions, including if you:</span></p>
<ul class="Disc">
<li>have <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span></li>
<li>have recently had a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span></li>
<li>have heart or blood vessel disorders</li>
<li>suffer from <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> or recurrent <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span></li>
<li>are pregnant or plan to become pregnant. It is not known if RECTIV will harm your unborn baby.</li>
<li>are breast-feeding or plan to breast-feed. It is not known if the components of RECTIV will harm your child if you breast-feed.</li>
</ul>
<p>RECTIV may lower your blood pressure. When getting up from a lying or sitting position, you should get up slowly, otherwise you might feel <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span>.</p>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take</span>, including prescription and non-prescription medicines, vitamins and herbal supplements. Other medicines may affect how RECTIV works. RECTIV may also affect how other medicines work.</p>
<p>Specifically, tell your doctor if you are taking any of the following:</p>
<ul class="Disc">
<li>other nitroglycerin containing products</li>
<li>a medicine for <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span> (male <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>), for example sildenafil, tadalafil or vardenafil (see the section above 'Who should not use RECTIV')</li>
<li>medicines used to treat high blood pressure</li>
<li>are taking aspirin, ergotamine (used to treat <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>) or are receiving tissue-type <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">plasminogen</span> activator (used to help dissolve blood clots formed in blood vessels in the heart, lungs and brain)</li>
<li>are to be given heparin. If so, close monitoring of your blood will be required as your dose of heparin may need to be altered. Please discuss with your doctor before stopping RECTIV.</li>
</ul>
<p><br><span class="Bold">How should RECTIV be used?</span></p>
<p><span class="Bold">Use RECTIV exactly as prescribed.</span> See detailed Patient Instructions for Applying RECTIV at the end of this Patient Information leaflet.</p>
<p>Treatment may be continued for up to 3 weeks. If your <span class="product-label-link" type="condition" conceptid="76458" conceptname="Rectal pain">anal pain</span> does not get better after using RECTIV you should talk to your doctor.</p>
<p><br><span class="Bold">What should I avoid while using RECTIV?</span></p>
<p>Do not drive or operate machinery immediately after applying RECTIV. If you feel dizzy or light-headed after applying the ointment do not drive or operate machinery until the <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> has stopped.</p>
<p>Avoid consuming alcohol while you are being treated with RECTIV as your blood pressure is more likely to be affected if you consume alcoholic beverages.</p>
<p><br><span class="Bold">What are the possible side effects of RECTIV?</span></p>
<p>RECTIV can cause serious side-effects: Stop using the ointment and seek medical attention immediately if you have an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>. You may have <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, lips, tongue or throat, or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>.</p>
<p>Common side-effects of RECTIV are:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headaches</span>, which can be severe. You could take painkillers for this (such as acetaminophen). If the <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> are unpleasant, you may need to ask your doctor whether you should stop using RECTIV.</li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>, faintness on standing, or light-headedness</li>
</ul>
<p>These are not all the possible side effects of RECTIV. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. For more information, ask your healthcare provider or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><br><span class="Bold">How should I store RECTIV?</span></p>
<ul class="Disc">
<li>Store at 20°-25°C (68°-77°F); excursions permitted between 15°-30°C (59°-86°F). [See USP Controlled Room Temperature].</li>
<li>Keep the tube tightly closed.</li>
<li>Use within 8 weeks of first opening.</li>
</ul>
<p><span class="Bold">Keep RECTIV out of the reach of children.</span></p>
<p>Do not use RECTIV after the expiry date which is stated on the label and carton after 'EXP.' The expiry date refers to the last day of that month.</p>
<p><br><span class="Bold">General information about RECTIV</span></p>
<p>Medicines are sometimes prescribed for conditions that are not mentioned in Patient Information leaflets. Do not use RECTIV for a condition for which it is not prescribed. Do not give RECTIV to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>This Patient Information leaflet summarizes the most important information about RECTIV. If you would like more information, talk to your healthcare provider. You can ask your pharmacist or healthcare provider for information about RECTIV that is written for health professionals.</p>
<p>For more information call 1-800-472-2634 or visit www.RECTIV.com.</p>
<p><span class="Bold">Patient Instructions for Use</span></p>
<p><span class="Bold">When do I apply the ointment?</span></p>
<p>Apply the ointment every 12 hours exactly as your doctor has told you to.</p>
<p><br><span class="Bold">How do I apply the ointment?</span></p>
<p>Cover your finger with plastic-wrap, a disposable surgical glove or a finger cot.</p>
<p>Lay the covered finger alongside the 1 inch dosing line marked on the side of the medicine box (see figure below) so that the tip of your finger is at one end of the dosing line. Starting at the tip of the finger, squeeze the ointment onto your finger for the same length marked on the box.</p>
<div class="Figure"><img alt="
rectiv-02
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=603aa9ed-54c4-4a35-ade4-690fa44850e4&amp;name=rectiv-02.jpg"></div>
<p>Refer to carton for accurate dosage guide.</p>
<p>Gently insert the finger with the ointment into the anal canal, up to the first finger joint. Carefully smear the ointment around the inner sides of the anal canal. If this cannot be achieved due to <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, application of the ointment should be made directly to the outside of the anus.</p>
<p><br><span class="Bold">What do I do after I have applied the ointment?</span></p>
<p>Throw away the finger covering in the garbage, out of the reach of children and pets. Wash your hands.</p>
<p><br><span class="Bold">What are the ingredients in RECTIV?</span></p>
<p>Active ingredient: nitroglycerin</p>
<p>Inactive ingredients: propylene glycol, lanolin, sorbitan sesquioleate, paraffin wax and white petrolatum.</p>
<p><br><span class="Bold">Manufactured by:</span></p>
<p>PHARBIL Waltrop GmbH<br>Im Wirrigen 25<br>45731 Waltrop<br>Germany</p>
<p><span class="Bold">Manufactured for:</span></p>
<p>Aptalis Pharma US, Inc.<br>100 Somerset Coporate Boulevard<br>Bridgewater, NJ 08807</p>
<br><p>RECTIV<span class="Sup">®</span> is a registered trademark of Aptalis Pharma US, Inc.</p>
<br><p>U.S. Patent No. 7,189,761</p>
<p><span class="Bold">Revised: July 2013</span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="splSectionPDP"></a><a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - OINTMENT 0.4% - CARTON</h1>
<p class="First">NDC 58914-301-80</p>
<p>RECTIV<br>(nitroglycerin)<br>Ointment 0.4%<br>For Intra-anal Use Only<br>30 g</p>
<div class="Figure"><img alt="carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=603aa9ed-54c4-4a35-ade4-690fa44850e4&amp;name=rectiv-03.jpg"></div>
<p></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Le285f5fd-d7f3-4801-99e9-37dc709cd223"></a><a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - OINTMENT 0.4% - TUBE</h1>
<p class="First"><img alt="tube" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=603aa9ed-54c4-4a35-ade4-690fa44850e4&amp;name=rectiv-04.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="L0d0c1539-4426-4359-9303-178368143eec"></a><a name="section-19"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - OINTMENT 0.4% - SAMPLE CARTON</h1>
<p class="First"><img alt="sample carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=603aa9ed-54c4-4a35-ade4-690fa44850e4&amp;name=rectiv-05.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="L243a9039-b0c0-4be2-840d-ed0b5700441b"></a><a name="section-20"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - OINTMENT 0.4% - SAMPLE TUBE</h1>
<p class="First"><img alt="sample tube" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=603aa9ed-54c4-4a35-ade4-690fa44850e4&amp;name=rectiv-06.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>RECTIV 		
					</strong><br><span class="contentTableReg">nitroglycerin ointment</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:58914-301</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">RECTAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>NITROGLYCERIN</strong> (NITROGLYCERIN) </td>
<td class="formItem">NITROGLYCERIN</td>
<td class="formItem">4 mg  in 1 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LANOLIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SORBITAN SESQUIOLEATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PARAFFIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PETROLATUM</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:58914-301-80</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">30 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:58914-301-85</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">5 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021359</td>
<td class="formItem">06/21/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Aptalis Pharma US, Inc.
							(033555307)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pharbil Waltrop GmbH</td>
<td class="formItem"></td>
<td class="formItem">343740283</td>
<td class="formItem">manufacture(58914-301), analysis(58914-301), pack(58914-301)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 7/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>713d6599-9d1c-46ad-9216-bad512105877</div>
<div>Set id: 603aa9ed-54c4-4a35-ade4-690fa44850e4</div>
<div>Version: 3</div>
<div>Effective Time: 20130705</div>
</div>
</div> <div class="DistributorName">Aptalis Pharma US, Inc.</div></p>
</body></html>
